Atomo Diagnostics secures $502,000 HIV self-test order for Africa

Atomo Diagnostics (ASX:AT1) has secured a purchase order worth $502,000 for its HIV self-tests, which will be supplied to an African country in March.

The tests, manufactured under the Mylan brand and funded by the Global Fund, are expected to contribute materially to Atomo's revenue.

Atomo is delighted to see continued demand for our HIV self-test in Africa, where access to high-quality, reliable, and discreet testing remains critical for those at risk of HIV," said Atomo Managing Director John Kelly.

At the time of reporting, Atomo Diagnostics’ share price was $0.041.